Viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two FGFR2C342Y/+ mouse models of Crouzon syndrome.

Craniosynostosis is the premature fusion of cranial bones. The goal of this study was to determine if delivery of recombinant tissue nonspecific alkaline phosphatase (TNAP) could prevent or diminish the severity of craniosynostosis in a C57BL/6 FGFR2C342Y/+ model of neonatal onset craniosynostosis o...

Full description

Bibliographic Details
Main Authors: Hwa Kyung Nam, Iva Vesela, Sara Dean Schutte, Nan E Hatch
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0234073
_version_ 1818917133586792448
author Hwa Kyung Nam
Iva Vesela
Sara Dean Schutte
Nan E Hatch
author_facet Hwa Kyung Nam
Iva Vesela
Sara Dean Schutte
Nan E Hatch
author_sort Hwa Kyung Nam
collection DOAJ
description Craniosynostosis is the premature fusion of cranial bones. The goal of this study was to determine if delivery of recombinant tissue nonspecific alkaline phosphatase (TNAP) could prevent or diminish the severity of craniosynostosis in a C57BL/6 FGFR2C342Y/+ model of neonatal onset craniosynostosis or a BALB/c FGFR2C342Y/+ model of postnatal onset craniosynostosis. Mice were injected with a lentivirus encoding a mineral targeted form of TNAP immediately after birth. Cranial bone fusion as well as cranial bone volume, mineral content and density were assessed by micro CT. Craniofacial shape was measured with calipers. Alkaline phosphatase, alanine amino transferase (ALT) and aspartate amino transferase (AST) activity levels were measured in serum. Neonatal delivery of TNAP diminished craniosynostosis severity from 94% suture obliteration in vehicle treated mice to 67% suture obliteration in treated mice, p<0.02) and the incidence of malocclusion from 82.4% to 34.7% (p<0.03), with no effect on cranial bone in C57BL/6 FGFR2C342Y/+ mice. In contrast, treatment with TNAP increased cranial bone volume (p< 0.01), density (p< 0.01) and mineral content (p< 0.01) as compared to vehicle treated controls, but had no effect on craniosynostosis or malocclusion in BALB/c FGFR2C342Y/+ mice. These results indicate that postnatal recombinant TNAP enzyme therapy diminishes craniosynostosis severity in the C57BL/6 FGFR2C342Y/+ neonatal onset mouse model of Crouzon syndrome, and that effects of exogenous TNAP are genetic background dependent.
first_indexed 2024-12-20T00:29:13Z
format Article
id doaj.art-e57e5cb473574edf8438590cfc3539e8
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-20T00:29:13Z
publishDate 2020-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-e57e5cb473574edf8438590cfc3539e82022-12-21T20:00:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01155e023407310.1371/journal.pone.0234073Viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two FGFR2C342Y/+ mouse models of Crouzon syndrome.Hwa Kyung NamIva VeselaSara Dean SchutteNan E HatchCraniosynostosis is the premature fusion of cranial bones. The goal of this study was to determine if delivery of recombinant tissue nonspecific alkaline phosphatase (TNAP) could prevent or diminish the severity of craniosynostosis in a C57BL/6 FGFR2C342Y/+ model of neonatal onset craniosynostosis or a BALB/c FGFR2C342Y/+ model of postnatal onset craniosynostosis. Mice were injected with a lentivirus encoding a mineral targeted form of TNAP immediately after birth. Cranial bone fusion as well as cranial bone volume, mineral content and density were assessed by micro CT. Craniofacial shape was measured with calipers. Alkaline phosphatase, alanine amino transferase (ALT) and aspartate amino transferase (AST) activity levels were measured in serum. Neonatal delivery of TNAP diminished craniosynostosis severity from 94% suture obliteration in vehicle treated mice to 67% suture obliteration in treated mice, p<0.02) and the incidence of malocclusion from 82.4% to 34.7% (p<0.03), with no effect on cranial bone in C57BL/6 FGFR2C342Y/+ mice. In contrast, treatment with TNAP increased cranial bone volume (p< 0.01), density (p< 0.01) and mineral content (p< 0.01) as compared to vehicle treated controls, but had no effect on craniosynostosis or malocclusion in BALB/c FGFR2C342Y/+ mice. These results indicate that postnatal recombinant TNAP enzyme therapy diminishes craniosynostosis severity in the C57BL/6 FGFR2C342Y/+ neonatal onset mouse model of Crouzon syndrome, and that effects of exogenous TNAP are genetic background dependent.https://doi.org/10.1371/journal.pone.0234073
spellingShingle Hwa Kyung Nam
Iva Vesela
Sara Dean Schutte
Nan E Hatch
Viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two FGFR2C342Y/+ mouse models of Crouzon syndrome.
PLoS ONE
title Viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two FGFR2C342Y/+ mouse models of Crouzon syndrome.
title_full Viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two FGFR2C342Y/+ mouse models of Crouzon syndrome.
title_fullStr Viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two FGFR2C342Y/+ mouse models of Crouzon syndrome.
title_full_unstemmed Viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two FGFR2C342Y/+ mouse models of Crouzon syndrome.
title_short Viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two FGFR2C342Y/+ mouse models of Crouzon syndrome.
title_sort viral delivery of tissue nonspecific alkaline phosphatase diminishes craniosynostosis in one of two fgfr2c342y mouse models of crouzon syndrome
url https://doi.org/10.1371/journal.pone.0234073
work_keys_str_mv AT hwakyungnam viraldeliveryoftissuenonspecificalkalinephosphatasediminishescraniosynostosisinoneoftwofgfr2c342ymousemodelsofcrouzonsyndrome
AT ivavesela viraldeliveryoftissuenonspecificalkalinephosphatasediminishescraniosynostosisinoneoftwofgfr2c342ymousemodelsofcrouzonsyndrome
AT saradeanschutte viraldeliveryoftissuenonspecificalkalinephosphatasediminishescraniosynostosisinoneoftwofgfr2c342ymousemodelsofcrouzonsyndrome
AT nanehatch viraldeliveryoftissuenonspecificalkalinephosphatasediminishescraniosynostosisinoneoftwofgfr2c342ymousemodelsofcrouzonsyndrome